Back to results
US 2025/0019387 A1Published application
Kras g12c inhibitors
AssigneeFrontier Medicines Corporation
InventorsSnahel PATEL, Hiroko TANAKA, Daniel A. ERLANSON, Philip A. GERKEN, John C. WIDEN, Monika Jane WILLIAMS, Irina DOTSENKO
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compounds and methods useful in the treatment and suppression of cancer, for example, useful for treating or suppressing cancers characterized by KRAS G12C. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Claims30
1-119. (canceled)
A compound of Formula II:
- or a salt thereof, or an isotopologue thereof, or a salt of an isotopologue thereof;
- wherein:
- RX is hydrogen;
- R1 is
- R2 is R2c;
- R3 is fluoro;
- R4 is fluoro, chloro, methyl, ethyl, or ethynyl;
- R2c is —NR15R16;
- R15 is methyl;
- R16 is
- R18 is hydrogen, —(CH2)z—NR22R23, —(CH2)u—R34, or R35;
- R19 is hydrogen;
- R20 is hydrogen;
- R22 and R23 are each methyl;
- z is 1;
- R34 is azetidine substituted with 1 instance of methyl, pyrrolidine substituted with 1 instance of methoxy or fluoro, 2-oxa-5-azabicyclo[2.2.1]heptane, 3-oxa-8-azabicyclo[3.2.1]octane, or 3-oxa-6-azabicyclo[3.1.1]heptane;
- u is 0 or 1;
- and
- R35 is
16 more elements
Dependencies are inferred from the claim text.